Skip to content

Ananda Developments - Research Roundup

Announcement provided by

Ananda Developments Plc · ANA

25/08/2023 12:01

Ananda Developments - Research Roundup
RNS Number : 4998K
Ananda Developments PLC
25 August 2023



Cannabinoid Medicine Research Roundup 

Issue Twenty-One


Ananda's ambition is to be a leading provider of high-quality cannabinoid medicines for the treatment of complex, chronic inflammatory pain conditions in the UK and for international markets.




We have now renamed this document the Cannabinoid Medicine Research Roundup. Over time we are seeing research become more targeted into mechanisms, pathways and individual cannabinoids in the attempt to understand how cannabis and/or its constituents work - individually and together. As we continue to develop our pharmaceutical grade cannabinoid medicines and the evidence needed for the NHS and other countries' medical systems to prescribe them, we believe that it is important to frame the conversation in the appropriate terms.


Since our last issue in June 2023 we have seen papers dealing with in vitro, in vivo and clinical evidence in areas as wide-ranging as the positive activity of the Endocannabinoid System and/or cannabidiol (CBD) in the clinic in untreated hypertension and in vivo of axon regeneration following injury, more evidence in epilepsy, and an in vitro acne model demonstrating the positive effect of CBD. See links to these articles at the bottom of this issue.


For this edition we have summarised three particularly interesting articles in further detail. If you are taking tamoxifen or know someone with sickle cell disease then you should be particularly interested. We also look at the role of CBD in aging - as if the rest of CBD's activities were not enough… it just might help you live longer!


CBD-oil as a potential solution in case of severe tamoxifen-related side effects


Tamoxifen is effective in the treatment of estrogen-receptor positive breast cancer and is recommended for two to three years for postmenopausal patients and up to ten years for premenopausal patients.


Unfortunately, tamoxifen can lead to bothersome side effects such as hot flashes, arthralgia, insomnia, and mood alterations. Forty percent of patients eventually discontinue tamoxifen therapy early, mainly due to side effects.


In this open label trial of 26 patients taking tamoxifen and tamoxifen + CBD, over 50 percent of the patients saw an improvement in the side effect symptoms compared to baseline.


The most common side effects which was also where most of the improvement was included hot flashes, joint pain, insomnia, sweats and mood swings.


The role of CBD in aging


Aging is a very complex biological process. Current research shows that there are at least 14 cellular and molecular hallmarks of aging: deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, compromised autophagy, inflammation, disturbance of the microbiome, etc.


Multiple biological processes are involved in aging, such as oxidative stress, inflammation, autophagy, proteostasis, cellular senescence and DNA damage. Here, this article highlighted the particular effect of CBD on oxidative stress, inflammation and autophagy and clarified its antiaging mechanism.


CBD and its effects on aging processes


CBD changed the life of this boy with sickle cell disease


Patients with sickle cell disease (SCD) suffer from both acute and chronic pain, whose pathophysiology involves not only red blood cell sickling with subsequent vaso-occlusion leading to ischemia reperfusion injury, but also neurogenic inflammation, possibly mediated by mast cell activation.


Chronic pain affects approximately 40 percent of patients with SCD, and its management is often a difficult challenge for clinicians. Indeed, morphine, which has long been considered the

reference analgesic for acute pain, may paradoxically worsen chronic pain, by promoting mast cell activation and degranulation, leading to the release of mast cell mediators such as substance P or histamine.


This 15-year-old man with SCD had a history of 5 to 10 hospitalisations per year - two of these were for 56 and 49days because of the inefficacy of conventional analgesics, including intravenous paracetamol, nalbuphine, morphine (PCA), nefopam, ketamine, and amitriptyline.


The patient suffered from daily chronic pain in the lumbar spine, thorax, and right knee, described as intense and permanent with overlying cutaneous hyperesthesia and intermittent tingling sensation. He was later started at 3mg/kg of CBD per day gradually increasing over a month to 22mg/kg/day in 3 doses.


Two weeks were enough to observe a complete regression of pain in the lumbar spine, thorax, and right knee. The patient discontinued CBD one month after introduction due to supply disruption, which caused recurrence of pain in the lumbar spine, thorax, and right knee after one week.


Resumption of treatment at the same dose allowed further regression of pain within one week. Since the beginning of CBD treatment, the patient has not required further hospitalization for VOC, with a follow-up of 10months.

Details are in the caption following the image


Additional articles


The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study


Injury-induced activation of the endocannabinoid system promotes axon regeneration


Real-world experience with cannabidiol as add-on treatment in drug-resistant epilepsy


In vitro acne disease model from inertial focusing effect for studying the interactions between sebocyte glands and macrophages.


The Directors of the Company accept responsibility for the contents of this announcement.  




+44 (0)7463 686 497 

Chief Executive Officer 

Melissa Sturgess 

Finance Director 

Jeremy Sturgess-Smith 


+44 (0)20 3470 0470 

Corporate Finance 

Richard Morrison 

Harry Davies-Ball 

Corporate Broking 

Abigail Wayne 

Rob Rees 



About Ananda Developments  


Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions. 


For more information, please visit: 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

ANA announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal